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Cytokeratin 18 (CK18) fragments are released into circulation during epithelial cell 
death. M30 (reflect caspase cleaved CK18 fragment) and M65 (reflect total CK18 
fragment) enzyme-linked immunosorbent assay (ELISA) detects circulating CK18 
fragments released during caspase-dependent or total cell death, respectively; thus, 
CK18 has the potential of being a biomarker for epithelial cancers. In the present study, 
we investigated the serum levels of M30 and M65 in patients with gastric cancer, 
determined correlation of these levels with clinical features, and evaluated the 
usefulness of these enzymes as diagnostic and prognostic markers. 
We enrolled 54 gastric cancer patients and 12 healthy volunteers in this study. We 
measured the serum levels of M30 and M65 by quantitative ELISA.  
The levels of M30 and M65 in gastric cancer patients were significantly higher than 
those in healthy volunteers (P = 0.001, P < 0.001). The enzyme levels were elevated 
with the progress of gastric cancer. The sensitivity and specificity of M30 as a 
diagnostic marker were 67.5% and 90.9%, respectively, and those of M65 were 70.1% 
and 90.9%, respectively. The serum levels of M30 and M65 in patient with early 
gastric cancer were elevated in 38.1% and 66.7%, respectively. Further, increased 
serum level of M65 is an independent indicator of poor prognosis (P = 0.036). 
The serum levels of M30 and M65 may be useful biomarkers for gastric cancer as 
diagnostic markers that can reflect the extent of cancer. Moreover, M65 levels can be 
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used as a prognostic indicator. 
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Biomarkers are substances that are objectively measured and evaluated as indicators of 
biological and pathological processes or pharmacological responses to a therapeutic 
intervention. Biomarkers hold a great promise for the detection, diagnosis, and 
prognosis of cancer because of their ability in identifying unique molecular signatures 
detrimental to certain pathophysiological states [1]. An ideal marker has high 
sensitivity and specificity for diagnosis, its level should correlate with the disease 
status and response to treatment, and it should be easily and reproducibly measured. 
However, the biomarkers currently available for the management of solid tumors do 
not fulfill all the above criteria and, therefore, are not presently recommended for 
screening of the general population [2]. 
Gastric cancer is one of the leading causes of cancer-related death worldwide. The 
prognosis of metastatic gastric cancer remains poor despite the recent improvements in 
the therapeutic methods [3]. The diagnosis and treatment of gastric cancer requires 
further improvement; therefore, it is important to identify an ideal biomarker for 
diagnosis and prognosis. The level of the biomarker is expected to be measured using 
less invasive methods and monitored easily, for example, by a simple blood test. 
Several serum biomarkers have been used in gastric cancer. Carcinoembryonic antigen 
(CEA) and carbohydrate antigen (CA) 19-9 are established as biomarkers for advanced 
gastric cancer. However, these biomarkers were unable to detect early-stage gastric 
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cancer; some patients with advanced gastric cancer had normal serum levels of these 
biomarkers. Thus, development of novel biomarkers for gastric cancer that can be 
routinely used in clinical practice is required. 
Circulating biomarkers of cell death have been proposed as useful biomarkers for 
patients with cancer and the other critical illness [4, 5]. The levels of nucleosomal 
DNA, Fas-ligand, cytochrome c, and a variety of cytoskeletal components have been 
measured as circulating biomarkers of cell death [6–9]. The products that are released 
into circulation by cancer cells upon their death can be measured. These biomarkers 
can be used clinically as diagnostic and prognostic factors of cancer and to predict the 
outcome of anticancer therapies. The biomarkers are increasingly being used in trials 
of new anticancer therapies. 
Cytokeratin 18 (CK18) is a member of the intermediate filament family of cytoskeletal 
proteins, is widely expressed in epithelial and endothelial cells, and accounts for 
approximately 5% of the total cell protein [10]. CK18 is usually expressed during 
oncogenic transformation [11], and it is expressed in gastric cancer [12]. Moreover, 
CK18 expression correlated with lymph node metastases, tumor differentiation, and 
tumor invasion of gastric cancer [13]. 
CK18 may be a useful indicator of gastric cancer, because it is an accepted marker of 
cell death [14]. Several types of cell death such as apoptosis, necrosis, and autophagy 
have been described as a part of the ongoing disease process. The possibility that death 
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of cancer cells may generate products into circulation, which can be detected in the 
serum, has an important diagnostic potential. A novel method based on the 
measurement of different molecular forms of CK18 can be used to investigate the 
modes of epithelial cell death. CK18 fragments are released into the circulation during 
necrotic or apoptotic cell death. Enzyme-linked immunosorbent assays (ELISAs) have 
been developed to measure the circulating levels of caspase-cleaved and total soluble 
CK18 fragments. M30 and M65 antibodies can be used in ELISA to detect the different 
forms of CK18 released into circulation during caspase-dependent or total cell death, 
respectively, and these antibodies are potential biomarkers of epithelial cancers [15]. 
Activated caspases 3, 7, and 9 cleave CK18 during apoptosis, which leads to collapse 
of the cytoskeleton and subsequent formation of apoptotic bodies; subsequently, the 
proteolytic fragments of caspase-cleaved CK18 are released into circulation [16, 17]. 
M30-Apoptosense® ELISA detects a neoepitope specific to apoptosis caused by 
caspase-mediated cleavage of CK18 at aspartate 396 (CK18asp396), and thus, M30 is 
a selective biomarker of apoptosis. Conversely, necrosis of epithelial cells releases 
full-length CKs into circulation after breakdown of the cell membrane. Monoclonal 
antibody M6 and M5 detects total soluble CK18 fragments that contain full-length 
epitope of the protein; thus, M65 can be used to detect CK18 fragments released from 
necrotic cells in addition to those from apoptotic cells [16, 18]. Both assays may 
provide clinically useful information for the management of patients with epithelial 
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cancers. This assay can be used clinically for patients with several epithelial cancers 
such as head and neck tumors, endometrial carcinoma, testicular cancer, prostate 
cancer, breast cancer, lung cancer, colorectal cancer, and pancreatic cancer [18-24]. In 
addition, serum levels of M30 and M65 are increased in patients with advanced 
gastrointestinal adenocarcinoma [2, 25]. Recently, increased serum levels of M30 and 
M65 have been reported in patients with advanced gastric cancer [26]. 
The objectives of this study were to compare serum M30 (reflect caspase cleaved 
CK18 fragment) and M65 (reflect total CK18 fragment) levels between healthy 
volunteers and patients with gastric cancer and to determine whether the levels of these 
markers are correlated with the extent of cancer and prognosis. Here, we have carefully 
evaluated the correlation between serum M30 and M65 levels and clinical features and 
the diagnostic and prognostic significance of these levels in patients with gastric cancer 
to assess their clinical potential as biomarkers. To our knowledge, previous reports 
were concerned with advanced gastric cancer, this is the first report on increased serum 
both M30 and M65 levels in patients with gastric cancer even in an early stage and that 
these levels are closely correlated with extension of gastric cancer; further, serum level 




Patients and serum collection 
We enrolled 54 patients diagnosed with gastric cancer confirmed by histological 
examination at Kanazawa university hospital; blood samples of the patients were 
collected before treatment. The disease status of patients were assessed according to 
the American Joint Commission on Cancer (AJCC)/International Union against Cancer 
(UICC) TNM classification [27]. Patients with a history of malignancies, diabetes 
mellitus, or uncontrolled infection were excluded from the study. Control blood 
samples were collected from 12 healthy volunteers (age; 28-72 (median; 58), 8 males 
and 4 females). Blood samples of patients were collected before any cancer therapy. 
Blood samples collected from patients and controls were stored into dry tubes, and the 
sera were centrifuged at 1000g for 10 min within 30 min of sampling. The samples 
were stored at −80°C until analysis. Written informed consent was obtained before 
starting the study from all patients and healthy volunteers for using data obtained from 
hematological and clinical examinations to be used for research purpose. The study 
was performed according to the guidelines of the Medical Ethics Committee of the 
Kanazawa university hospital in compliance with the Helsinki Declaration. 
Assay procedure to determine the serum levels of CK18 
Samples were assayed in duplicate for CK18asp196 using the M30-Apoptosense® 
ELISA (PEVIVA AB, Bromma, Sweden), which is a one-step in vitro immunoassay for 
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the quantitative determination of the apoptosis-associated CK18asp396 (M30) 
neoepitope in the serum and plasma. M65®-ELISA (PEVIVA) is a one-step in vitro 
immunoassay for the quantitative determination of total soluble CK18 in the serum and 
plasma. Both the procedures were performed according to the manufacturer’s 
instructions. Mean of the duplicate values were used for analysis.  
Detection of serum tumor markers 
Serum levels of CEA and CA19-9 before treatment were routinely measured in patients 
with gastric cancer at our institute. Serum CEA levels less than 5 ng/mL and serum 
CA19-9 level less than 35 U/mL were considered to be normal values as per the 
manufacturer’s protocol. 
Statistical analysis 
Statistical analyses were performed with the Statistical Package for Social Sciences 
(SPSS) statistical software version 11.0. Continuous data were described using median 
values (± standard deviation) obtained by Mann–Whitney U-test or Kruskal–Wallis test 
for non-parametric comparisons of continuous data. In addition, receiver operator 
curve (ROC) analysis was performed; sensitivities, specificities, and area under curves 
(AUC) were calculated using ROC analysis for diagnosis and death. Survival data 
were analyzed using the Kaplan–Meier method and log-rank test was performed for the 
comparison of survival curves. Cox’s proportional hazards regression was used for 
multivariate analysis. Prognostic variables of univariate significance were selected for 
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Serum levels of M30 and M65 in patients and controls 
Patient demographics and tumor characteristics are summarized in Table 1. Patients 
with gastric cancer showed a wide range of serum levels of M30; reflect 
caspase-cleaved CK18 (111.4–1121.3 U/L); serum M30 levels were statistically higher 
in patients than in controls (184.1 ± 179.6 vs. 144.3 ± 10.6, P = 0.001, Fig. 1). 
Similarly, patients with gastric cancer showed a wide range of serum levels of M65; 
reflect total soluble CK18 (106.1–2290.0 U/L), and these values were statistically 
higher in patients than in controls (204.2 ± 392.9 vs 104.4 ± 36.1, P < 0.001, Fig. 1). 
Thus, serum M65 and M30 levels were positively correlated with the presence of 
gastric cancer. Furthermore, the serum levels of M30 and M65 statistically correlated 
with clinical factors, including depth of tumor invasion, lymph node metastasis, distant 
metastasis, and clinical stage; in addition, M65 levels correlated with the histological 
type (Table 1). The levels of both M30 and M65 significantly correlated with the extent 
of disease of the patient. 
Usefulness of M30 and M65 levels as diagnostic markers of gastric cancer 
To determine whether the serum levels of M30 and M65 could be used as diagnostic 
markers of gastric cancer, we measured the serum levels of each biomarker using ROC 
analyses for calculating the best cut-off value for diagnosis. The best cut-off value, 
AUC, and the range of 95% confidence interval (CI) for M30 were 155.0 U/L, 0.801, 
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and 0.810 to 0.914, respectively, and those for M65 were 142.2 U/L, 0.919, and 0.837 
to 1.001, respectively. M30 has a sensitivity of 67.5% and a specificity of 90.9%, while 
M65 has a sensitivity of 70.1% and a specificity of 90.9% in distinguishing between 
patients and healthy volunteers. The sensitivities of M30 and M65, respectively, 
according to clinical stages were as follows: Stage I, 38.1% and 66.7%; Stage II, 
66.7% and 33.3%; Stage III, 100% and 100%; and Stage IV, 82.6% and 95.7%. High 
values of CEA were found in 12 (22.2%) of the 54 patients (0% in Stage I and II, 50% 
in Stage III, and 39.1% in Stage IV), high values of CA19-9 were found in 12 (22.2%) 
of the 54 patients (8.3% in Stage I and II, 16.7% in Stage III, and 39.1% in Stage IV). 
These results suggest that the serum levels of M30 and M65 may be used as good 
diagnostic biomarkers. The sensitivity of serum M30 and M65 levels was superior to 
that of CEA and CA19-9 levels in all stages, including the early stage of gastric cancer, 
and thus, the former may be suitable for population screening. 
Survival analysis 
The median follow-up period was 26.5 months (range, 4.5–40.5 months), and the 
median overall survival was 20.4 months (range, 1.4–40.5 months). To evaluate the 
association between serum levels of M30, M65, CEA, and CA19-9 and patient survival, 
we measured the serum levels of each biomarker using ROC analyses for calculating 
the best cut-off value for prediction of death. The best cut-off value, AUC, and the 
range of 95% CI for M30 were 184.8 U/L, 0.705, and 0.558 to 0.852, respectively, and 
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those for M65 were 199.3 U/L, 0.829, and 0.712 to 0.947. The level of CEA was 3.1 
ng/mL; AUC, 0.613 (95% CI, 0.459–0.767), and the level of CA19-9 was 21.5 mg/mL; 
AUC, 0.647 (95% CI, 0.492–0.802). Univariate analysis of overall survival was 
performed by Kaplan–Meier method and log-rank test was performed for clinical 
findings; the cut-off values of each biomarker were calculated using these tests. 
Clinical stage (P < 0.001), CEA level (P = 0.015), M65 level (P = 0.017), and 
histological type (P = 0.034) were significantly associated with survival (Table 2). The 
values of M30 were high in patients with poor prognosis, but these values were not 
statistically significant (P = 0.061). The above prognostic variables of univariate 
significance were selected for inclusion in the multivariate model. Multivariate 
analysis revealed that independent significant prognostic factors were clinical stage (P 
= 0.033) and serum M65 level (P = 0.036, Table 2). Increased serum M65 levels were 
associated with poorer survival on univariate analysis as dichotomized variable (log 
rank, P = 0.017; Fig. 3), and on multivariate analysis as a continuous data (Cox, P = 




Serum CK18 are increased in tumors such as head and neck tumors, endometrial 
carcinoma, testicular cancer, prostate cancer, breast cancer, lung cancer, colorectal 
cancer, and pancreatic cancer [18-24]. Increase in serum M30 levels in cancer were 
reported for the first time by Uneo et al. in breast cancer patients [28]. Uneo et al. 
showed that M30 levels were significantly higher in recurrent disease than in primary 
breast cancer and healthy subjects, and M30 levels correlated with tumor volume. M30 
and M65 levels were also increased in patients with advanced gastrointestinal 
adenocarcinoma [2, 25]. Yaman E et al. reported that serum M30 and M65 levels were 
increased in patients with advanced gastric cancer, and only M30 levels reflected the 
tumor load [26]. There were no reports that indicate correlation between serum M30 
and M65 levels and cancer extent. In the present study, we found that the serum levels 
of M30 and M65 were significantly higher in patients with gastric cancer than in 
healthy volunteers. The levels of M30 and M65 statistically correlated with the extent 
of gastric cancer, reflecting high tumor burden and they were also elevated in early 
stage.  
Classic tumor markers, CEA and CA19-9, are correlated with tumor load in advanced 
gastric cancer. However, these markers are not useful for the detection of early-stage 
gastric cancer. In addition, many patients with advanced gastric cancer have normal 
levels of these markers. Classical biomarkers of gastric cancer do not have sufficient 
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sensitivity for population screening. In the present study, diagnostic sensitivities of 
M30 (67.5%) and M65 (70.1%) were higher than those of classical tumor markers 
(CEA and CA19-9, both 22.2%). In addition, the levels of M30 and M65 are closely 
correlated with extent of cancer, depth, lymph node metastasis, distant metastasis, and 
clinical stage. In patient with early gastric cancer, they were elevated in 38.1% and 
66.7%, respectively. These findings suggest that M30 and M65 were sensitive 
diagnostic markers of gastric cancer. 
Serum M30 levels have been reported to be a prognostic marker in some tumor types 
such as endometrial carcinoma, testicular cancer, lung cancer, and colorectal cancer 
[19, 21-23]. Ueno et al. [28] reported that increased serum levels of M30 in breast 
cancer patients had no prognostic impact. In contrast, Ulukaya et al. showed that 
increased serum M30 levels in lung cancer patients were associated with shorter 
median survival time [19]. Serum levels of M30 and M65 significantly reflected the 
prognosis of testicular germ cell cancer [21]. Yaman E et al. reported that serum M30 
level was an independent prognostic factor in patients with gastric cancer, but serum 
M65 level was not a prognostic factor [26]. In Bilici’s study, univariate analysis 
showed that M30 and M65 levels were associated with progression-free survival in 
patients with advanced gastric cancer, but these findings could not be confirmed by 
multivariate analysis [29]. In our study, M30 levels were not statistically correlated 
with prognosis; in contrast, M65 levels were associated with a shorter survival time in 
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patients with gastric cancer. Increase of cell death, especially necrotic cell death might 
be reflecting aggressive behavior of cancer. In present study, serum M65 levels were 
correlated with cancer extent and histological type in either. M65 might reflect the 
cancer status including both the volume and the behavior of cancer cells, thus they 
associated with poorer outcome. And M65 might indicate the aggressive behavior of 
cancer cells than M30 in gastric cancer. The conflicting results obtained in different 
studies may be related to the low number patients examined in previous studies, and 
further studies with a greater number of patients are required to confirm the importance 
of serum M30 and M65 levels. 
The source of serum CK18 fragments is not clear. The depth, status of lymph node 
metastasis and distant metastasis respectively correlated with serum M65 levels. They 
reflect the volume of cancer cells directly. These results indicate that serum CK18 
fragments were mainly released from tumor cells; not from healthy cells affected by 
cancer. 
Serum levels of M30 and M65 were investigated as a potential biomarker for treatment 
response. Fluctuations in serum M30 and M65 levels during chemotherapy were 
discussed as useful early indicators of response to chemotherapy. M30 levels had 
significant relationship with response to therapy in breast cancer and lung cancer [19, 
30, 31]. Moreover, M65 and M30 levels reflect chemotherapy-induced changes in 
testicular germ cell cancer [21]. CK18 levels before initiation of chemotherapy may be 
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an indicator of tumor response to the chemotherapy in patients with advanced 
gastrointestinal adenocarcinomas [2]. On the other hand, the levels of M30 were 
increased during chemotherapy in patients with gastrointestinal cancer, which was also 
related with response to the therapy [25]. We conducted studies on changes in serum 
M30 and M65 levels as an early predictor for the effect of chemotherapy in gastric 
cancer.  
The serum levels of M30 (reflect caspase cleaved CK18 fragment) and M65 (reflect 
total CK18 fragment) may be biomarkers for gastric cancer and highly sensitive 
diagnostic markers that can reflect the extent of cancer. Moreover, M65 levels can be 
used as a prognostic indicator. Further studies with a greater number of patients are 
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Figure 1 - Serum M30 and M65 levels in healthy volunteers and patients. 
Serum M30 and M65 levels were statistically higher in patients than in controls (P = 
0.001). They were positively correlated with the presence of gastric cancer. Horizontal 
solid lines represent median values, boxes represent interquartile ranges, and 
whiskers represent ranges. 
Figure2 - Overall survival rate of patients with gastric cancer, deference according to serum 
M65 level. 
Increased serum M65 levels were associated with poorer survival on univariate 
analysis as dichotomized variable (log rank, P = 0.017; Fig. 3), 
 
Tables 
Table1 - Patient characteristics and serum M30 level, serum M65 level. 
The serum levels of M30 and M65 statistically correlated with clinical factors, 
including depth of tumor invasion, lymph node metastasis, distant metastasis, and 
clinical stage; in addition, M65 levels correlated with the histological type. 
Table 2 - Survival analysis. 
Clinical stage (P < 0.001), CEA level (P = 0.015), M65 level (P = 0.017), and 
histological type (P = 0.034) were significantly associated with survival in univariate 
analysis. Multivariate analysis revealed that independent significant prognostic factors 
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were clinical stage (P = 0.033) and serum M65 level (P = 0.036).  
Table Ⅰ. Patient characteristics and serum M30 level, serum M65 level. 
 
characteristics n serum M30 (U/L) p-value serum M65 (U/L) P-value 
All 54 184.1 ± 179.6  204.2 ± 392.9  
Age (31-80, median 68)   0.992  0.695 
  -68 26 174.1 ± 245.4  183.2 ± 527.9  
  69- 28 188.4 ± 65.9  234.5 ± 187.3  
Sex   0.874  0.768 
male 44 184.1 ± 141.4  204.2 ± 308.5  
female 10 188.6 ± 179.6  204.2 ± 392.9  
Histological type   0.295  0.027 
  intestinal type 25 182.4 ± 58.2  171.5 ± 121.6  
  diffuse type 29 191.4 ± 252.4  305.9 ± 535.6  
Depth of tumor invasion   0.003  0.010 
T1 23 154.6 ± 38.3  152.6 ± 134.8  
T2 12 190.0 ± 88.5  284.1 ± 174.5  
T3 15 211.0 ± 302.7  251.7 ± 657.7  
T4 4 183.4 ± 149.8  199.3 ± 342.8  
Lymph node metastasis   0.001  0.001 
  N0 25 154.9 ± 27.9  147.7 ± 62.8  
  N1 6 213.7 ± 83.3  321.0 ± 138.5  
  N2 8 196.2 ± 285.0  238.6 ± 590.7  
  N3 15 249.4 ± 239.2  425.2 ± 530.4  
Distant metastasis   0.041  0.001 
  M0 41 182.6 ± 63.4  195.0 ± 150.4  
  M1 13 249.4 ± 321.7  457.0 ± 668.3  
Clinical stage   0.001  0.001 
  Ⅰ 21 154.6 ± 25.9  213.7 ± 83.3  
  Ⅱ 3 220.3 ± 198.8  139.1 ± 437.9  
  Ⅲ 7 210.3 ± 42.3  299.9 ± 92.2  
  Ⅳ 23 211.0 ± 250.9  311.0 ± 541.2  











Table Ⅱ. Survival analysis. 
 
 overall survival 
 univariate analysis multivariate analysis 
 P Hazard ratio (95% CI) P 
age 0.548 - - 
gender 0.850 - - 
histological type 0.034 0.451 (0.123 – 1.651) 0.229 
clinical stage < 0.001 2.153 (1.107 – 4.189) 0.033 
M30 0.061 - - 
M65 0.017 1.001 (1.000 – 1.002) 0.036 
CEA 0.015 1.658 (0.443 – 6.213) 0.669 

































M65 < 199.3 U/L 
M65 > 199.2 U/L 
Log rank – P=0.017 
Katsunobu Oyama
Figure 2. Overall survival rate of patients with gastric cancer, 
deference according to serum M65 level.
